Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eflornithine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | BLM | P54132 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | ARG1 | P05089 | 3/20 | 0.62 |
| ▸ | ARG2 | P78540 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflornithine, (S)- SCHEMBL60698 | 1.00 | ODC1 (1.00) | ODC1LMNABLMKDM4EMAPT | |
| D-Eflornithine SCHEMBL60699 | 1.00 | ODC1 (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL8581344 | 1.00 | ODC1 (1.00) | ODC1LMNABLMKDM4EMAPT | |
| D-Eflornithine SCHEMBL7208883 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL6779168 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL3244711 | 0.98 | ODC1 (0.96) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine, (S)- SCHEMBL6779172 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL3022583 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine, (S)- SCHEMBL1322403 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| D-Eflornithine SCHEMBL3244719 | 0.98 | ODC1 (0.96) | ODC1LMNABLMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29032 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3368029-B1 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | USWM LLC (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137642-A1 | METHODS OF TREATING PATIENTS HAVING TYPE 1 DIABETES WITH EFLORNITHINE | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108451-A1 | COMPOSITIONS FOR THE MANAGEMENT OF HIRSUTISM | MAJEED ANJU (IN) | 2026-04-23 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-0211354-A2 | Nucleosides and their use as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-25 | — | — | EP | claimed |
| EP-0198893-A1 | HAIR GROWTH MODIFICATION. | HANDELMAN JOSEPH H (US) | 1986-10-29 | — | — | EP | claimed |
| WO-1986002269-A1 | HAIR GROWTH MODIFICATION | HANDELMAN, JOSEPH, H. (US) | 1986-04-24 | — | — | WO | claimed |
| EP-0162413-A2 | Polyamine for use as a medicine in the treatment of neoplasms | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-11-27 | — | — | EP | claimed |
| US-4499072-A | Process for treating diseases with ODC inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-02-12 | — | — | US | claimed |
| US-4496588-A | HALOMETHYL DERIVATIVES OF A-AMINO ACID | MERRELL TORAUDE ET COMPAGNIE (FR) | 1985-01-29 | — | — | US | claimed |
| US-4433051-A | Derivatives of α-difluoromethylornithine useful in analysis | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IS) | 1984-02-21 | — | — | US | claimed |
| US-4413141-A | INHIBITOR OF ORNITHINE DECARBOXYLASE | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-11-01 | — | — | US | claimed |
| US-4336054-A | AMINO ACIDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1982-06-22 | — | — | US | claimed |
| US-4330559-A | 2,5-DIAMINO-2-FLUOROMETHYLPENTANOIC ACIDS OR DERIVATIVES | MERRELL-TORAUDE ET CIE (FR) | 1982-05-18 | — | — | US | claimed |